Two Amino Acids Administered Intranasally Could Cure Parkinson’s Disease

In their quest for a cure for Parkinson’s disease scientists have developed two peptides. These peptides when administered intranasally slowed the death of dopaminergic neurons thereby improving the symptoms of Parkinson’s. Initial results in laboratory mice are very encouraging.

Man With Parkinson's

Man With Parkinson’s

Parkinson’s disease is the most common motor pathology in the world. Millions of people worldwide suffer from this degeneration of dopaminergic neurons, which causes many symptoms, including the characteristic tremor. The culprit of dopaminergic neuronal death is thought to be insoluble aggregates of abnormally shaped α-synuclein, the so-called preformed fibrils. They are also present in Lewy bodies and are the cause of several neurodegenerative diseases, including Parkinson’s disease.

Read Also: French Study Shows That Lysosomes Act as Trojan Horses in Parkinson’s Disease

Usually, neurons can eliminate α-synuclein aggregates by exocytosis. These could then be transferred to other neurons by a hitherto unknown mechanism. Microglia, the immune cells of the brain are activated by preformed fibrils and release pro-inflammatory cytokines. Chronic inflammation in the brain accelerates the death of dopaminergic neurons and the release of α-synuclein.

Promising intranasal treatment

Scientists at Rush University Medical Center in Chicago proposed an approach to fix this problem that has proven successful in vitro and now in vivo in laboratory mice. They have developed two peptides, small proteins that inhibit α-synuclein-induced microglial activation. The first, called wtTIDM, targets TLR2, an innate immunity receptor that activates microglia. By preventing TLR2 from communicating with other elements that are responsible for the cascade reaction, the wtTIDM peptide prevents microglial activation. A second peptide, wtNBD, acts in the same way but binds elsewhere.

Read Also: University of Wisconsin Researchers Use Stem Cells to Treat Parkinson’s

Both peptides were administered intranasally to mice with a large number of pre-formed fibrils to trigger a form of Parkinson’s disease. Following this treatment, microglia inflammatory activity was significantly reduced, as was α-synuclein propagation, thereby protecting the dopaminergic neurons. This biological effect is reflected in an improvement in health status. The treated mice showed improved locomotor and balance abilities as well as other motor functions.

Human trials are still needed

“If these results can be replicated in patients, it will be a major breakthrough in the treatment of this devastating neurological disorder,” concludes Kalipada Pahana, who led the study which was published in Nature Communications. There are drugs that slow the progression of Parkinson’s disease, such as levodopa, which replenishes the dopamine deficiency caused by neuronal death. It slows the loss of motor skills but does not prevent the death of dopaminergic neurons. For patients with the most severe impairments, deep brain stimulation may be an alternative.

Read Also: Antibiotics May Increase Your Risk of Having Parkinson’s Disease

Scientists are currently working on several lines of research, such as immunotherapy and gene therapy, to cure this disease, which we so far can only slow down.

References

Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo

FEEDBACK:

Conversation

Want to Stay Informed?

Join the Gilmore Health News Newsletter!

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.

By clicking "Subscribe," I agree to the Gilmore Health and . I also agree to receive emails from Gilmore Health and I understand that I may opt out of Gilmore Health subscriptions at any time.